Neuralink has filed with the SEC to raise $649 million in a new equity offering, which it expects to close within a year. This move follows recent investor commitments totaling approximately $600 million and pushes the company’s valuation past $9 billion.
Founded in 2016, Neuralink is developing brain-computer interfaces (BCIs) to help individuals with paralysis or neurological conditions regain autonomy. Its N1 implant, featuring flexible electrode threads and wireless recharging, translates brain signals into digital commands. The system is implanted using Neuralink’s proprietary R1 surgical robot, designed to avoid brain vasculature.
Earlier this year, Neuralink made headlines after a human patient successfully used its BCI to control a cursor with thought alone—a major milestone in the company’s clinical progress.
The equity raise is expected to accelerate development and expand trials, including applications like robotic arm control for patients with severe mobility loss.
Follow MEDWIRE.AI for updates on brain-computer interface innovations.
